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ABSTRACT
Background: Although the dangers of smoking, and the
benefits of quitting, are well established and understood
in the West, smoking remains popular among Asian men.
We investigated the associations between smoking
(including ex-smoking) and major causes of mortality in
Asian men and women, and compared with Australians
and New Zealanders (ANZ).
Methods: An overview of 34 cohort studies in the Asia
Pacific region involving 512 676 individuals (81% from
Asia), followed up for a median of 6.7 years (20 804
deaths).
Results: Mortality rates for cause-specific and all causes
of mortality were systematically higher for current
compared with never smokers. Hazard ratios (HR) for
overall and cause-specific mortality comparing current-
smokers with never smokers, ex- smokers with current-
smokers and comparing numbers of cigarettes smoked
per day, were higher for ANZ than Asia (p,0.001). For
overall mortality, the HR (95% CI) comparing current-
smoking with not was 1.37 (1.23 to 1.53) and 1.33 (1.26
to 1.40) in Asian men and women respectively. The
corresponding figures in ANZ were 1.95 (1.81 to 2.09)
and 1.85 (1.69 to 2.02). The HR for quitting in ANZ was
0.67 (0.63 to 0.71) and 0.66 (0.58 to 0.74) in men and
women respectively. Quitting smoking had a significant
benefit among Asian men, the HR was 0.88 (0.81 to 0.97)
after ignoring the first 3 years of follow-up. There was no
evidence of benefit for Asian women, for whom ex-
smoking is rare.
Conclusions: Allowing for the recent uptake of smoking
in Asia, its effects are comparable to those observed in
ANZ. Stringent tobacco control measures and smoking
cessation strategies are urgently required in Asia.
In the West, smoking has long been known to be a
major cause of death and disability and has been
estimated to kill one out of two smokers prema-
turely.1 Similarly, in Western populations, the
benefits associated with quitting smoking have
been clearly demonstrated and in general, are
widely accepted by smokers and non-smokers.1–3
The vast majority of Westerners who currently
smoke are aware that smoking increases their
subsequent risk of cancer, cardiovascular disease
and respiratory illnesses. Consequently, a signifi-
cant proportion of smokers want, or have tried, to
quit the habit. Over the past three decades, most
developed countries have been successful in imple-
menting comprehensive anti-tobacco measures
that have resulted in substantial reductions in the
prevalence of smoking such that the number of
former smokers in countries such as the UK and
Australia now exceeds that of current smokers.4
Across large parts of Asia the situation is the
reverse and an estimated 50–70% of adult men are
reported to be current smokers.5 In most Asian
countries smoking cessation is a relatively infre-
quent event; a likely consequence of the wide
cultural acceptance that smoking continues to
enjoy in the region (particularly among men).4 6 7
For example, data from the China National
Prevalence Survey (1996) showed the prevalence
of former smokers to be only 10%, and that the
most common reason for quitting was ill health.
Further, 60% of Chinese smokers have never
contemplated quitting.6
Raising public awareness in Asia as to the health
consequences caused by smoking is a vital first step
in implementing effective tobacco control strate-
gies and potentially would go some way towards
reversing its cultural acceptability. However, only a
small fraction of the studies that have reported on
the associations between smoking and mortality
have been conducted in these countries. Therefore,
the objective of this current study is to provide
reliable evidence as to the impact of smoking, and
the likely benefits associated with quitting the
habit, on total mortality and major causes of
mortality among populations of the Asia Pacific
region using data from the Asia Pacific Cohort
Studies Collaboration (APCSC).8
METHODS
Details of study identification, data collection and
event verification in the APCSC are described
elsewhere.8 Briefly, studies were included if they
had continued follow-up for at least 5000 person-
years and had recorded vital status at the end of
follow-up. Studies were excluded if entry was
dependent upon a particular condition or risk
factor. Mortality was classified according to the
9th Revision of the International Classification of
Diseases (ICD). The outcomes investigated in this
analysis were all causes of death, cancer, cardio-
vascular disease, respiratory disease (ICD9: 490–
496, 466, 480–486, 136.3, 507, 514, 460–465,
467–479, 487–489, 497–506, 508–513, 515–519,
010–019, 137) and injuries (including violence,
suicide and any other trauma, ICD9: 800–999).
Studies were classified as Asian if their participants
were recruited from mainland China, Hong Kong,
Japan, Korea, Singapore, Taiwan or Thailand; and
ANZ if from Australia or New Zealand.
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Analyses were based on individual participant data and
restricted to participants over 20 years of age. All data on
cigarette smoking were based on self-report at the time of entry
into one of the included studies. This analysis comprises studies
that recorded whether individuals were current, former or never
smokers; participants were grouped as ‘‘current’’ if they smoked
currently, ‘‘never smokers’’ if they had never smoked and
‘‘former smokers (or ex-smokers)’’ if they had smoked in the
past but reported having already quit at the time of entry. For
those studies collecting information on the amount of cigarettes
smoked per day (CPD), current smokers were classified in three
approximately equal sized groups: ,20, 20 and .20 CPD; 20
cigarettes corresponds to one standard pack.
Cox proportional hazard models, adjusted for age and
stratified by study, were used to derive the hazard ratios and
corresponding 95% CIs for death for ‘‘ex-smokers’’ as compared
with ‘‘current’’ smokers and for ‘‘current’’ as compared with
‘‘never smoked’’. Since the effect of quitting on the reduction of
mortality risk might have been underestimated due to
participants stopping smoking because of health-related issues,
a sensitivity analysis was also performed in which the first
3 years of follow-up were excluded. Hazard ratios for dose–
response of CPD were estimated using ‘‘never smoked’’ as the
reference group. Confidence intervals were calculated using the
method of floating absolute risks.9 Region- and sex-specific
results were derived and heterogeneity of the estimated hazard
ratios between groups was investigated through fitting interac-
tion terms for region by smoking and sex by smoking.
Heterogeneity of the estimated hazard ratios between three at
risk age groups (,65, 65–74, >75) was assessed using a x2 test.
RESULTS
Baseline characteristics and mortality data
Of the 44 studies in APCSC, 34 (25 in Asia) provided data on
current smoking status that distinguished former from never
smokers. A total of 22 studies provided data on cigarette
consumption for current smokers (table 1). Overall, information
on 512 676 participants (81% from Asia) were included in the
analyses.
Smoking habits varied by region and by sex. At baseline, in
ANZ, 14% of women and 20% of men declared themselves as
current smokers, and 21% and 43% of women and men,
respectively, were reported as having quit smoking. In Asia, 59%
of men were current smokers and 11% were former smokers; the
corresponding figures in women were 3% and 0.9%. Female and
male smokers in ANZ and male smokers in Asia had the same
mean CPD (14); Asian women smoked, on average, 9 CPD.
In ANZ, during a median follow-up of 8.3 years, 3241 women
and 5831 men died (table 2). In both sexes, cardiovascular
disease was the leading cause of death (40%), followed closely
by cancer, (35%). Approximately 7% of deaths were due to
respiratory disease and 4% to injury. In Asia, over a median
follow-up of 5.6 years a total of 3334 women and 8398 men
died. The most common cause of death in men was cancer
(38%) and in women cardiovascular disease (40%). Injury
fatalities were more common in Asian men and women (10%
and 6%, respectively) compared with participants from ANZ.
The age-adjusted mortality rates for all-cause mortality were
systematically higher among current smokers compared with
never smokers (table 2). In general, in ANZ mortality rates
among former smokers were higher, or similar, to those of never
smokers whilst in Asia they were higher or similar to those of
current-smokers in Asia. The rates differences indicated a
greater absolute effect of smoking on mortality risk in ANZ
compared with Asia. For example, for all causes mortality the
rates difference between current smokers and never smokers
was equal to 80.1 and 48.8 per 10 000 person years in ANZ men
and women respectively. The corresponding figures in Asia were
22.9 and 31.2 per 10 000 person-years.
Hazard ratios for smoking-related mortality
In ANZ, age-adjusted hazard ratios for current smokers, as
compared with never smokers, showed a significant excess risk for
all the outcomes except for injury mortality in women (table 3).
There was no evidence of heterogeneity between sexes for any of
the outcomes (range of p values for interaction: 0.41–0.59).
Compared with never smokers, current smokers had risks of
mortality from all-site cancer and respiratory illness that were
approximately two and five times higher, respectively;
mortality from cardiovascular disease was also 60 to 80%
higher among current smokers compared with never smokers.
Smoking was associated with a smaller increase in risk, of
about 50% and 30%, for injury and other causes respectively.
In Asia, associations were less strong than those in ANZ for
cancer, cardiovascular, respiratory and all-cause mortality (all
p values for regional interaction ,0.001). Similar to ANZ, there
were no evidence of any sex difference in the magnitude of the
associations for any of the outcomes (p value for sex interaction:
0.43–0.96). Current smokers had a 61% (95% CI 29 to 100)
greater risk of cancer in women and 44% (95% CI 32 to 57) in
men. In both sexes, cardiovascular mortality risk increased by
more than 40%, all-cause mortality by about one-third, and
respiratory risk by about one-quarter.
There was a strong log-linear association between the number
of cigarettes smoked per day and the risk of total mortality in
both regions and in both sexes (all p values for linear trend
,0.001; fig 1). The dose response relationship was stronger in
ANZ than in Asia (p value for region interaction for men
,0.001, for women = 0.014). For example, comparing those
who smoked 20 or more cigarettes per day to never smokers, the
hazard ratio and 95% CI for all-cause mortality was 1.52 (1.36
to 1.70) and 1.30 (0.32 to 5.19) in men and women in Asia and
2.59 (2.32 to 2.89) and 2.94 (2.42 to 3.57) in men and women in
ANZ. In Asia and ANZ there was no indication of a sex
interaction (p value for interaction >0.23).
Hazard ratios for mortality among former smokers
In ANZ, mortality risks were significantly reduced in former
smokers as compared with current smokers for all the outcomes,
with the exception of ‘‘other causes’’ in both sexes and injury in
women. The risk of all-cause mortality was reduced by about
one-third and similar reductions were estimated for the risk of
cancer and cardiovascular disease; the risk of respiratory death
was reduced by about two-thirds; and that of injury by 45% in
men.
In Asia, there were no significant differences in most hazard
ratios comparing former smokers with current smokers. The
hazard ratio for all-cause mortality comparing former with
current smokers was 0.98 (0.92, 1.05) in men and 1.03 (0.86, 1.24)
in women. When the data were left-censored to exclude deaths
during the first 3 years of follow-up, the hazard ratios comparing
former with current smokers in males from Asia were 0.88 (0.81,
0.97) for all-cause mortality and 0.82 (0.70–0.96) for cancer.
Similarly the HRs were decreased but remained non
significant, for cardiovascular and for mortality from other
causes (table 3). By contrast, the hazard ratio for respiratory
mortality was significantly increased in former versus current
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smokers: 1.37 (1.03, 1.84). By comparison, left-censoring did
not influence the results from Australia.
Age specific hazard ratios
Smoking was associated with a significant increased risk of all-
cause mortality at all ages but it had a relatively stronger impact
among individuals at risk at ‘‘younger’’ ages in ANZ and Asia
(p values for age interaction ,0.001 in ANZ and 0.007 in Asia;
table 4). In both regions the hazard ratio for all-cause mortality
among current smokers was significantly higher among
individuals less than 65 years of age compared with those aged
over 75 years (p value for interaction ,0.001). The benefits
derived from quitting smoking were significant at all ages in
ANZ, being greater among younger individuals who presumably
would have been smoking for fewer years and had quit at
younger age. From the youngest to the oldest age at risk group,
quitting appeared to decrease the risk of mortality in ANZ,
respectively by 43, 37 and 24% (p value for age interaction
,0.001). In Asia, where the effect of quitting smoking was less
clear, only those in the youngest age group who had quit had a
significant 10% reduction in the risk of all-cause mortality
compared with continuing smokers.
CONCLUSIONS
Our findings, based on data from over half a million individuals,
show that cigarette smoking is associated with a significant
increase in the risk of cancer, cardiovascular disease and any-
cause mortality, for both sexes in Asian and Caucasian
populations of the Asia Pacific region. Smoking is also a
significant risk factor for fatal respiratory disease and deaths
from ‘‘other causes’’ except in the case of Asian women, among
whom smoking is rare. Furthermore, there was evidence of a
positive association of smoking with death from injury in
cohorts from ANZ. The excess risks of mortality from all causes






















Australia Newcastle 5929 1983–94 8.9 52 50 17.8 18.4 17 36.7 27.6 19
Australia ALSA 1610 1992–93 4.6 78 48 23.3 7.7 13 62.1 7.7 16
Australia ANHF 9277 1989–90 8.3 43 51 19.8 21.1 16 32.4 27.2 19
Australia Busselton 7789 1966–81 26.5 45 52 11.9 24.4 3 25.3 43.9 3
Australia Canberra 821 1991–92 9.4 77 45 24.9 9.7 NA 62.3 12.7 NA
Australia Melbourne 41 285 1990–94 8.5 55 59 22.0 9.0 17 44.7 14.5 21
Australia Perth 10 230 1978–94 5.7 45 48 18.3 21.1 15 31.3 29.6 18
Australia WAAAA 12 203 1996–99 3.2 72 0.0 NA NA NA 59.9 10.9 13
NZ Fletcher Challenge 10 326 1992–94 5.8 44 28 28.1 18.4 11 33.3 25.5 12
ANZ Subtotal 99 470 1966–99 8.3 53 45 20.6 14.2 14 42.8 20.4 14
China Anzhen 8378 1991 4.3 54 55 2.4 10.3 9 8.9 50.8 14
China Beijing Aging 2092 1992 4.8 70 51 9.8 14.2 8 23.0 45.5 13
China CISCH 2167 1992–93 3.3 44 51 0.6 0.8 7 7.2 54.7 14
China Fangshan 2619 1991–92 3.6 47 67 2.2 21.5 4 6.2 74.6 8
China Guangzhou
Occupational
166 695 1985–98 7.3 42 22 0.0 1.3 7 0.5 60.4 13
China Seven Cities
Cohorts
10 811 1987 2.7 54 55 1.9 16.8 NA 8.0 57.0 NA
China Xi’an 1695 1976 19.7 44 34 0.5 11.9 10 2.2 54.0 15
China Yunnan 6581 1992 4.5 56 3 NA NA NA 14.3 69.7 12
Hong Kong Hong Kong 2983 1985–91 2.5 79 57 17.6 10.8 7 41.2 29.1 11
Japan Akabane 1834 1985–86 11.0 54 56 0.3 1.0 8 20.8 61.9 23
Japan Civil Service
Workers
9240 1990–92 6.7 47 33 3.1 11.4 NA 25.7 50.9 NA
Japan Hisayama 1601 1961 24.6 56 56 0.9 16.7 NA 4.0 76.2 NA
Japan Konan 1226 1987–95 6.4 52 55 1.0 4.7 11 14.3 61.6 22
Japan Miyama 1073 1988–90 6.6 61 56 2.9 7.0 12 24.9 57.7 21
Japan Ohasama 2240 1992–93 4.1 60 64 0.5 2.3 NA 11.4 51.1 NA
Japan Saitama 3615 1986–90 11.0 55 62 2.3 7.7 14 21.0 62.5 21
Japan Shibata 2350 1977 20.0 57 58 0.3 4.4 10 5.7 72.2 20
Japan Shigaraki Town 3730 1991–97 4.4 57 59 1.6 8.0 13 22.4 59.0 22
Japan Shirakawa 4640 1974–79 17.5 48 54 0.4 5.4 NA 7.7 69.9 NA
Singapore Singapore Heart 2321 1982–97 14.6 41 49 0.7 3.0 NA 13.8 40.5 NA
Singapore Singapore NHS92 3305 1992 6.2 39 52 0.4 3.0 NA 11.7 34.8 NA
S. Korea KMIC 160 242 1992 4.0 44 33 0.5 0.4 NA 21.3 57.5 NA
Taiwan CVDFACTS 5729 1988–96 6.0 47 55 0.1 1.5 NA 7.2 48.0 NA
Taiwan Kinmen 2545 1993–97 2.9 63 49 1.3 5.2 NA 16.9 50.3 NA
Thailand EGAT 3494 1985 11.4 43 23 1.8 6.3 NA 17.9 54.3 NA
Asia Subtotal 413 206 1961–98 5.6 44.8 32 0.9 3.3 9 10.7 58.6 14
Sudies were: ALSA, Australian Longitudinal Study of Aging; ANHF, Australian National Heart Foundation; ANZ, Australians and New Zealanders; CISCH, Capital Iron and Steel
Company Hospital Cohort; EGAT, Electricity Generating Authority of Thailand; KMIC, Korean Medical Insurance Company; WAAAA, Western Australian Abdominal Aortic Aneurysm
Screening Program.
CPD, number of cigarettes smoked per day by current smokers; NA, not available.
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Men Women Men Women
n Rate (SE) n Rate (SE) n Rate (SE) n Rate (SE)
Cancer:
Never 458 19.1 (1.0) 676 16.5 (0.7) 703 18.7 (0.8) 785 11.8 (0.4)
Ex 1005 27.1 (1.2) 235 19.0 (1.4) 429 28.6 (1.5) 38 22.4 (5.4)
Current 591 46.2 (2.0) 261 36.0 (2.4) 2019 28.0 (0.7) 103 17.8 (1.9)
Cardiovascular:
Never 567 22.0 (1.0) 844 18.0 (0.7) 598 19.7 (0.9) 1051 16.6 (0.5)
Ex 1057 24.7 (1.7) 194 14.9 (1.2) 376 27.7 (1.5) 74 34.5 (6.3)
Current 723 55.6 (2.2) 249 34.5 (2.4) 1481 27.5 (0.8) 193 32.5 (2.5)
Respiratory:
Never 63 2.0 (0.3) 99 2.2 (0.2) 165 5.8 (0.5) 268 4.0 (0.2)
Ex 197 3.7 (0.3) 31 2.4 (0.5) 125 8.6 (0.8) 38 7.8 (2.3)
Current 194 14.4 (1.1) 72 10.0 (1.2) 350 8.1 (0.5) 43 6.4 (1.1)
Injury:
Never 63 3.7 (0.5) 68 2.0 (0.3) 198 4.5 (0.4) 188 2.8 (0.2)
Ex 70 3.1 (0.5) 20 1.9 (0.5) 98 7.2 (1.1) 3 6.5 (5.6)
Current 76 6.0 (0.8) 27 3.5 (0.7) 502 5.7 (0.3) 16 5.1 (1.7)
Other:
Never 210 7.8 (0.61) 310 7.6 (0.5) 354 9.7 (0.6) 452 6.3 (0.3)
Ex 396 9.7 (0.70) 78 6.7 (0.8) 191 12.7 (1.0) 23 10.7 (4.0)
Current 161 12.6 (1.06) 77 11.0 (1.4) 810 12.0 (0.5) 59 11.5 (2.2)
All causes:
Never 1361 54.7 (1.7) 1997 46.1 (1.2) 2018 58.4 (1.4) 2744 42.1 (0.8)
Ex 2725 68.3 (1.9) 558 44.9 (2.1) 1219 84.5 (2.7) 176 82.9 (11.0)
Current 1745 134.8 (3.4) 686 94.9 (3.9) 5161 81.3 (1.4) 414 73.3 (4.4)
The overall Asia Pacific Cohort Studies Collaboration population served as the base for age standardisation.
ANZ, Australians and New Zealanders; SE, standard error.




p Value*Men Women Men Women
All cancer:
Current vs never 2.08 (1.83 to 2.36) 2.14 (1.85 to 2.48) 0.59 1.44 (1.32 to 1.57) 1.61 (1.29 to 2.00) 0.43
Ex vs current 0.72 (0.65 to 0.80) 0.65 (0.54 to 0.78) 1.02 (0.91 to 1.14) 1.10 (0.74 to 1.63)
Ex vs current{ 0.68 (0.60 to 0.78) 0.65 (0.53 to 0.80) 0.82 (0.70 to 0.96) 0.73 (0.37 to 1.44)
All cardiovascular:
Current vs never 1.78 (1.59 to 2.00) 1.59 (1.38 to 1.84) 0.46 1.41 (1.28 to 1.56) 1.42 (1.21 to 1.66) 0.94
Ex vs current 0.67 (0.60 to 0.74) 0.71 (0.58 to 0.85) 1.03 (0.92 to 1.16) 0.98 (0.74 to 1.30)
Ex vs current{ 0.68 (0.61 to 0.77) 0.70 (0.56 to 0.86) 0.88 (0.75 to 1.04) 0.99 (0.66 to 1.05)
Respiratory:
Current vs never 5.42 (4.04 to 7.27) 4.56 (3.33 to 6.24) 0.59 1.24 (1.03 to 1.50) 1.23 (0.89 to 1.70) 0.96
Ex vs current 0.34 (0.27 to 0.42) 0.32 (0.21 to 0.49) 1.18 (0.95 to 1.48) 1.26 (0.79 to 2.01)
Ex vs current{ 0.31 (0.24 to 0.40) 0.26 (0.15 to 0.44) 1.37 (1.03 to 1.84) 1.17 (0.58 to 2.34)
Injury:
Current vs never 1.69 (1.20 to 2.39) 1.46 (0.93 to 2.29) 0.59 1.07 (0.90 to 1.26) 1.35 (0.79 to 2.30) 0.60
Ex vs current 0.55 (0.39 to 0.77) 0.80 (0.45 to 1.45) 0.76 (0.61 to 0.95) 0.91 (0.26 to 3.19)
Ex vs current{ 0.52 (0.32 to 0.85) 0.86 (0.42 to 1.79) 1.41 (0.80 to 2.48) 1.80 (0.21 to 15.57)
Other (including unknown):
Current vs never 1.26 (1.02 to 1.55) 1.38 (1.07 to 1.78) 0.50 1.23 (1.09 to 1.40) 1.16 (0.88 to 1.54) 0.81
Ex vs current 0.94 (0.78 to 1.15) 0.75 (0.55 to 1.04) 0.90 (0.76 to 1.06) 0.83 (0.50 to 1.37)
Ex vs current{ 0.99 (0.78 to 1.28) 0.77 (0.52 to 1.12) 0.69 (0.45 to 1.08) 0.90 (0.21 to 3.85)
All causes:
Current vs never 1.95 (1.81 to 2.09) 1.85 (1.69 to 2.02) 0.41 1.37 (1.23 to 1.53) 1.33 (1.26 to 1.40) 0.65
Ex vs current 0.67 (0.63 to 0.71) 0.66 (0.58 to 0.74) 0.98 (0.92 to 1.05) 1.03 (0.86 to 1.24)
Ex vs current{ 0.66 (0.62 to 0.72) 0.65 (0.57 to 0.74) 0.88 (0.81 to 0.97) 1.00 (0.75 to 1.32)
*p Value for sex interaction.
{After censoring of the first 3 years of follow-up.
ANZ, Australians and New Zealanders.
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were apparent at all ages but were consistently greater among
younger individuals in Asia and ANZ.
For all-cause mortality the excess risks associated with
smoking were significantly higher in ANZ compared with
Asia. Current smokers in ANZ had twice the risk compared
with never smokers, whereas in Asia, current smokers had a
one-third higher risk. The magnitude of these estimates, as well
as the smaller observed effect among Asian cohorts, are
consistent with previous findings from studies conducted in
Australia,10 New Zealand11 and Europe1 12–14 China,15–18
Taiwan,19 20 Japan21–23 and Korea.24
Although the relative risks associated with smoking were
generally lower in Asia compared with ANZ, particularly for
women, this is likely to reflect reported differences in the
maturity of the smoking epidemic across the region5 25–28 rather
than it being indicative of any physiological, or genetic,
differences between Asians and non-Asians.29 A shorter length
of study follow up among the Asian cohorts may also have
underestimated the effects, given that the risks of smoking are
determined not only by the amount smoked and the age at
which smoking commences, but also by the duration of
smoking. Consequently, the full impact of smoking on health
in the region has yet to be realised and is unlikely to be apparent
for at least another decade.
Differences in the reasons for quitting may also account for
some of the variation in the impact of smoking between the
regions. In China, most former smokers quit due to an already
established illness,6 by which time, stopping smoking would
have little effect on altering disease progression; hence such
patterns of smoking cessation are associated with only modest
reductions in relative risk or in some instances, an actual
increase in the risk (due to the problem of reverse causality).
Although our analyses did not adjust for education or socio
economic status or personality, variables that were not collected
in the APCSC, our finding of a positive association between
smoking and mortality from injury in cohorts from ANZ is
consistent with findings from a meta-analysis of four studies
from the USA and Northern Europe.30 In that meta-analysis, a
dose–response relationship between smoking and injuries was
observed, and this persisted after adjustment for alcohol
consumption and socioeconomic status. It has been suggested
that the apparent association between smoking and injury
might be confounded by personality type; individuals who
smoke are postulated to engage in risky behaviours resulting in
an increased propensity towards incurring an injury.31 Studies
have also shown that people with mental illness are about twice
as likely to smoke as others.32 33 Thus, whether the relationship
is causal or due to confounding remains a matter of ongoing
debate and for investigation by future studies.
Importantly, findings from the current study demonstrate
the effectiveness of quitting smoking on reducing the risk of
mortality across all populations in the Asia Pacific region,
although the benefits tended to be greater for former smokers in
cohorts from ANZ compared with those from Asia. In ANZ,
quitting smoking was associated with a reduction of 30% in the
risk of all-cause mortality compared with one of about a 10%
among male former smokers in Asia. The benefits of quitting
smoking were also greater among younger individuals (,65
years) presumably because they have smoked for fewer years
compared with older individuals, and older individuals often
quit too late after having serious illnesses.
We found an increased risk of 37% in respiratory mortality in
former versus current smokers. This is likely due to reverse
causality and is consistent with the increased risk of chronic
Figure 1 Hazard ratios for all-cause
mortality by number of cigarettes per day
(base = never smokers), by region and
sex. Lines show 95% CIs. ANZ,
Australians and New Zealanders.
Table 4 Hazard ratios and 95% CIs for all-cause mortality by region and age at risk group
Status/age group ANZ p Value* Asia p Value*
Current vs never:
,65 2.21 (1.98 to 2.47) ,0.001 1.35 (1.27 to 1.42) 0.007
65–75 2.35 (2.13 to 2.59) 1.40 (1.29 to 1.52)
75+ 1.47 (1.35 to 1.61) 1.18 (1.09 to 1.28)
Ex vs current:
,65 0.57 (0.51 to 0.64) ,0.001 0.90 (0.83 to 0.99) 0.003
65–75 0.63 (0.58 to 0.70) 1.18 (1.04 to 1.35)
75+ 0.76 (0.69 to 0.83) 1.04 (0.92 to 1.17)
*p Value for age interaction
ANZ, Australians and New Zealanders.
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obstructive pulmonary disease in former smokers in a cohort
study of Chinese retired men18 and similar findings for deaths
due to respiratory disease in Taiwan.19 We attempted to remove
the potential for reverse causality by eliminating the first 3 years
of follow-up, the overall effect of which was a general lowering
of the risks among male former smokers in Asia (with the
exception of respiratory illness). By comparison, left-censoring
had no impact in ANZ, which lends support to the aforemen-
tioned idea that individuals in Asia are more likely to quit
smoking due to reasons of ill health.
The current analyses are limited by the lack of information on
the duration and age at which smoking commenced, both of
which are more important determinants of subsequent risk than
the actual amount smoked.34 Related to this, we also lacked data
on the time since quitting smoking and consequently, we were
unable to examine how risk may have evolved over time among
former-smokers. Furthermore, APCSC analyses were based on
self-reported cigarette consumption at baseline, and informa-
tion on change in smoking habits during follow-up was
available from too few studies to enable any meaningful
analysis to be undertaken. Finally, the individual studies used
different methods to verify cause of death, which would have
resulted in an underestimation of the risks associated with
smoking. Moreover, these methods will have varied over time
and the lack of standardisation could have had some unpre-
dictable effect on the results.
Currently, interventions that only focus on preventing people
from starting to smoke will do little to prevent an estimated 1
billion deaths due to smoking by the end of the 21st century,
100 million of which will occur in China alone.4 A low level of
awareness as to the harmful effects of cigarette smoking and of
the health and economic benefits associated with quitting,35 the
mistaken belief that quitting could be harmful to some chronic
smokers, combined with a lack of comprehensive tobacco
control programmes,6 may explain much of the ongoing
popularity of smoking in China and other Asian countries.
Effective tobacco control strategies and implementation of
smoke-free policies36 are urgently needed across Asia in order to
assist many smokers to quit and thus to prevent the large
number of deaths that are predicted to occur if current smoking
patterns persist.27
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What this paper adds
c Despite the relative immaturity of the smoking epidemic
across large parts of Asia, smoking is associated with a
substantial increase in the risk of mortality from all causes.
c Quitting smoking reduces the risk of premature death in Asia
where smoking cessation is a rare occurrence.
c Culturally-specific tobacco control strategies are urgently
needed across Asia to curb the smoking epidemic.
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